deltatrials

Gastric adenocarcinoma Trials in Paris, France

Conditions / Gastric adenocarcinoma / Paris, France

Gastric adenocarcinoma has been the subject of sustained clinical investigation across multiple research sites.

13 total trials for this combination

Showing top 10 of 13 trials

Trials

NCT ID Title Status Phase
NCT02443883 A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer COMPLETED PHASE2
NCT05059444 ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation RECRUITING
NCT03959293 Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma ACTIVE_NOT_RECRUITING PHASE2
NCT05476796 Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer RECRUITING PHASE2
NCT04739202 Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) UNKNOWN PHASE2
NCT06333314 Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI RECRUITING PHASE2
NCT01882933 D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma ACTIVE_NOT_RECRUITING PHASE3
NCT04604132 Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma TERMINATED PHASE1/PHASE2
NCT05002127 A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) ACTIVE_NOT_RECRUITING PHASE2/PHASE3
NCT02443324 A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer COMPLETED PHASE1

Related Pages